LLY

1,070

+0.18%↑

JNJ

224.04

+0.12%↑

ABBV

216.27

+2.36%↑

UNH

382.22

+1.25%↑

MRK

116.41

+1.09%↑

LLY

1,070

+0.18%↑

JNJ

224.04

+0.12%↑

ABBV

216.27

+2.36%↑

UNH

382.22

+1.25%↑

MRK

116.41

+1.09%↑

LLY

1,070

+0.18%↑

JNJ

224.04

+0.12%↑

ABBV

216.27

+2.36%↑

UNH

382.22

+1.25%↑

MRK

116.41

+1.09%↑

LLY

1,070

+0.18%↑

JNJ

224.04

+0.12%↑

ABBV

216.27

+2.36%↑

UNH

382.22

+1.25%↑

MRK

116.41

+1.09%↑

LLY

1,070

+0.18%↑

JNJ

224.04

+0.12%↑

ABBV

216.27

+2.36%↑

UNH

382.22

+1.25%↑

MRK

116.41

+1.09%↑

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

20.86 -2.98

Buy Sell

Overview

Share price change

24h

Current

Min

20.68

Max

21.52

Key metrics
By Trading Economics
Income	-270M 3.6M
Sales	-16M 268M
P/E Sector Avg	9.738 50.102
EPS	0.02
Profit margin	1.357
Employees	796
EBITDA	-31M -4.6M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+50.23% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-114M 3.7B
Previous open	23.84
Previous close	20.86

News Sentiment

By Acuity

25%

75%

57 / 344 Healthcare

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jun 2026, 20:30 UTC

Earnings

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 Jun 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 Jun 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 Jun 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 Jun 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 Jun 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 Jun 2026, 21:00 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 Jun 2026, 20:46 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:38 UTC

Earnings

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 Jun 2026, 20:21 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:12 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Product Rev $594M

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Loss $177M >PANW

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

50.23% upside

12 Months Forecast

Average 32.33 USD 50.23%

High 38 USD

Low 23 USD

Based on 14 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

57 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.